Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
Alphabet Q4 2025 preview. Is the pace of AI monetization sustainable?
Market wrap๐จ European stocks outpace Wall Street๐Nasdaq sell-off to continue?
Eli Lilly surges 7% after earnings driven by obesity drugs ๐
Record revenues for AMD. Is the company confirming its leading position?